Expert Ratings for First Wave BioPharma
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have given bullish ratings to First Wave BioPharma (NASDAQ:FWBI) with an average price target of $11.6, a decrease of 27.5% from the previous average price target of $16.00. No bearish or neutral ratings were reported.
June 29, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First Wave BioPharma has received bullish ratings from five analysts over the past three months. The average price target is $11.6, a decrease of 27.5% from the previous average price target of $16.00.
The bullish ratings from five analysts indicate a positive outlook for First Wave BioPharma. However, the decrease in the average price target suggests that while the outlook is positive, expectations have been adjusted downwards. This could potentially impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100